The company passed the "three" project municipal acceptance
Release time:
2020-07-22
Company Passed Municipal Acceptance of "Three" Projects
News 2019 10# October 31 , Jinhua Economic and Information Bureau organized experts to carry out the second-stage acceptance of the management innovation project of Jianfeng Group's "Three" pilot enterprises. The construction time of the acceptance project is 2017 10 to 2018 12 .
2015 November 27, with the consent of the provincial government, peak was identified as the second batch of "three" cultivation pilot enterprises in Zhejiang province. the cultivation direction is management innovation, and the cultivation period is from 2016 to 2018 12 . During the whole cultivation period, the company conscientiously fulfilled the work objectives in the "three" cultivation pilot enterprise responsibility letter signed with the provincial, municipal and district governments, and successively invested more than ,000 ,000 yuan in information management. by the end of 2018 , the company had completed all the tasks in the cultivation period. 2017 10 , the company passed the phased acceptance of the "three" project. At the
NC system and supply chain financial business integration system, pharmaceutical company production quality management system, pharmaceutical logistics ERP system. Among the three projects, the financial NC system and the supply chain financial business integration system make use of the advanced and highly integrated data processing to solve the problem of "disconnection" among the units within the group and the departments within the enterprise, making the units and departments seamless, to a certain extent, it has solved the problems of "repeated data price drop" and "poor information transmission" in the process of management informatization of health technology companies, thus improving the efficiency of information system in many aspects and greatly reducing the cost of information use, with the accuracy of accounting reaching 95% ; In terms of purchasing business control, reduce the workload of 40% for purchasing statisticians; In terms of expense reimbursement business control, directly shorten the time of enterprise employee expense reimbursement 60% . The pharmaceutical company's production quality management system, through the construction of a unified enterprise operation platform, the construction of a drug quality control system that meets international standards, the automatic collection and recording of online production, quality and other industrial data, realizes the whole process of drug production under the predetermined target Monitoring and visualization of production process parameters; electronic batch production and inspection records of the drug production process, to the greatest extent, it conforms to the supervision concept of GMP data integrity and quality traceability. After the completion of the project, it is expected to reduce the defective rate of products by more than 20% , save the quality cost of 300 yuan /, increase the manufacturing execution efficiency by about 20%, and increase the production capacity by about 10% , energy utilization rate increased by more than 10% , saving nearly 10 million yuan per year and effectively improving execution efficiency. Pharmaceutical logistics ERP system, to achieve commodity category management and inventory optimization management, improve the turnover rate of goods. The docking with the medical insurance system is realized, the workload of store purchase, sale and storage input is reduced by 1/3, the reduction of staff and efficiency save labor costs, and the collection and management of member data realizes professional and accurate marketing. During the acceptance of
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page